DocMorris gibt die Ergebnisse des Rückkaufangebots für die ausstehenden Wandelanleihen mit Fälligkeit 2026 bekannt

^
DocMorris AG / Schlagwort(e): Anleihe
DocMorris gibt die Ergebnisse des Rückkaufangebots für die ausstehenden
Wandelanleihen mit Fälligkeit 2026 bekannt

13.11.2025 / 17:41 CET/CEST

---------------------------------------------------------------------------

Frauenfeld, 13. November 2025

Medienmitteilung

DocMorris gibt die Ergebnisse des Rückkaufangebots für die ausstehenden
Wandelanleihen mit Fälligkeit 2026 bekannt

Nach Abschluss der Rückkaufangebotsfrist am 12. November 2025 um 16:00 Uhr
MEZ gibt DocMorris die Ergebnisse des Rückkaufangebots für die ausstehenden
Wandelanleihen mit Fälligkeit 2026 bekannt ("Anleihen"). Die Anzahl der im
Rahmen des Rückkaufangebots angedienten Anleihen beträgt 72'713, was einem
Gesamtnennbetrag von CHF 72'713'000 entspricht.

Die Gesellschaft akzeptiert den vollen angedienten Betrag zu einem Kaufpreis
von CHF 1'035.00 pro Anleihe, was 103.50% des Nennwerts entspricht,
zuzüglich aufgelaufener und nicht bezahlter Zinsen. Der Abwicklungstag für
das Rückkaufangebot ist der 17. November 2025.

Nach Abwicklung des Rückkaufangebots bleiben 22'259 Anleihen, die einem
Gesamtnennbetrag von CHF 22'259'000, entsprechen, ausstehend.

Kontakt für Analysten und Investoren
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
E-Mail: ir@docmorris.com, Telefon: 41 52 560 58 10

Kontakt für Medien
Torben Bonnke, Director Communications
E-Mail: media@docmorris.com, Telefon: +49 171 864 888 1

Agenda

20. Januar Umsatz 2025
2026
19. März 2026 Jahresergebnis 2025 und Ausblick 2026 (Conference
Call/Webcast)
16. April Q1/2026 Trading update
2026
12. Mai 2026 Ordentliche Generalversammlung, Zürich

DocMorris
Die Schweizer DocMorris AG ist ein führendes Unternehmen in den Bereichen
Online-Apotheke, Telemedizin und Marktplatz mit starken Marken in
Deutschland und weiteren europäischen Ländern. Die Belieferung erfolgt
hauptsächlich aus dem hochautomatisierten Logistikzentrum im
niederländischen Heerlen. TeleClinic ist Deutschlands grösste
Telemedizinplattform, die Patienten mit mehr als 5'000 Ärzten verbindet. In
Südeuropa betreibt DocMorris führende Marktplätze für Gesundheits- und
Pflegeprodukte. Mit ihrem breiten Spektrum an Produkten und Dienstleistungen
verfolgt DocMorris die Vision, der führende digitale Gesundheitsbegleiter zu
werden, bei dem Menschen ihre Gesundheit mit einem Klick managen können. Im
Jahr 2024 erzielten rund 1'600 Mitarbeiter in Deutschland, den Niederlanden,
Spanien, Frankreich, Portugal und der Schweiz mit über 10 Millionen aktiven
Kunden einen Aussenumsatz von CHF 1'085 Mio. Die Aktien der DocMorris AG
sind an der SIX Swiss Exchange kotiert (Valor 4261528, ISIN CH0042615283,
Ticker DOCM). Weitere Informationen unter corporate.docmorris.com.

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE
RESPONSIBILITY OF DOCMORRIS AG (THE "COMPANY") AND DOCMORRIS FINANCE B.V.
(THE "ISSUER"). THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR
BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO
RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION
CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR
OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA,
CANADA, ITALY, JAPAN, SOUTH AFRICA OR IN ANY JURISDICTION TO WHOM OR IN
WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN
COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN
MAY BE RESTRICTED OR PROHIBITED BY LAW,

THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE
DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES.
THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN
JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER
INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND
OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY
CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
SECURITIES OF THE COMPANY OR THE ISSUER ARE NOT BEING PUBLICLY OFFERED
OUTSIDE OF SWITZERLAND. IN PARTICULAR, THE SECURITIES OF THE COMPANY AND THE
ISSUER REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES
UNLESS REGISTERED UNDER THE US SECURITIES ACT OF 1933 (THE "SECURITIES ACT")
OR OFFERED IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT. THE SECURITIES REFERRED TO HEREIN HAVE
NOT BEEN AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OR UNDER THE
APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN
EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR
DELIVERED WITHIN THE UNITED STATES OR TO OR FOR THE ACCOUNT OF U.S. PERSONS
EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER
THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT
OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS DOCUMENT DOES NOT CONSTITUTE
A PROSPECTUS ACCORDING TO THE SWISS FEDERAL ACT ON FINANCIAL SERVICES.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM
(EACH, A "RELEVANT STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE
SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS"
WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129)
("QUALIFIED INVESTORS"). IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED
EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN
MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE
FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS
AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE
ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, AND ANY
INVESTMENT ACTIVITY TO WHICH IT RELATES WILL ONLY BE ENGAGED IN WITH SUCH
PERSONS AND IT SHOULD NOT BE RELIED ON BY ANYONE OTHER THAN SUCH PERSONS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE,
"FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS MAY BE
IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS
"BELIEVES", "ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS",
"INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR
OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY,
PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING
STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY
FORWARD-LOOKING STATEMENTS REFLECT THE ISSUER'S OR THE COMPANY'S CURRENT
VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO
FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE
GROUP'S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY,
PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF
THE DATE THEY ARE MADE. EACH OF THE ISSUER, THE COMPANY, THE JOINT
BOOKRUNNERS AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY
OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING
STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW
INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THIS PUBLICATION CONSTITUTES NEITHER A PROSPECTUS OR A SIMILAR NOTICE WITHIN
THE MEANING OF THE ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL
SERVICES ACT OR UNDER ANY OTHER LAW OR A LISTING PROSPECTUS WITHIN THE
MEANING OF THE APPLICABLE LISTING RULES OF ANY STOCK EXCHANGE. ANY PURCHASE
OF BONDS OF THE ISSUER IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE
BASIS OF THE INFORMATION CONTAINED IN THE FINAL PROSPECTUS TO BE ISSUED BY
THE ISSUER IN CONNECTION WITH THE OFFERING. ANY PURCHASE OF SHARES OF THE
COMPANY IN THE PROPOSED OFFERING SHOULD BE MADE SOLELY ON THE BASIS OF
PUBLICLY AVAILABLE INFORMATION. THE INFORMATION IN THIS ANNOUNCEMENT IS
SUBJECT TO CHANGE THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR ISSUER
AND THE COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL
NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE
OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN ISSUER AND THE
COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS,
NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS
ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO
HEREIN.

IN CONNECTION WITH THE OFFERING OF THE BONDS AND THE SHARES, THE JOINT
BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE
SECURITIES IN THE OFFERINGS AS A PRINCIPAL POSITION AND IN THAT CAPACITY,
MAY RETAIN, PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH
SECURITIES AND OTHER SECURITIES OF THE ISSUER OR THE COMPANY OR RELATED
INVESTMENTS IN CONNECTION WITH THE OFFERINGS OR OTHERWISE. ACCORDINGLY,
REFERENCES IN THE PROSPECTUS RELATED TO THE BONDS, ONCE PUBLISHED, BEING
ISSUED, OFFERED, SUBSCRIBED, ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD
BE READ AS INCLUDING ANY ISSUE OR OFFER TO, OR SUBSCRIPTION, ACQUISITION,
PLACING OR DEALING BY THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES
ACTING IN SUCH CAPACITY. IN ADDITION, THE JOINT BOOKRUNNERS, AND ANY OF
THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS,
WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH
WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO
TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES OF THE ISSUER OR THE COMPANY.
THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH
INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR
REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS,
OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR
LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN
THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE
ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE ISSUER OR THE
COMPANY, THEIR SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL
OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE
AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS
ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.

NEITHER THIS ANNOUNCEMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS
OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER
TO ACQUIRE SECURITIES IN ANY JURISDICTION. ANY INVESTOR SHOULD MAKE HIS
INVESTMENT DECISION FOR THE PURCHASE OF THE SHARES ON PUBLICLY AVAILABLE
INFORMATION AND FOR THE PURCHASE OF THE BONDS SOLELY ON THE BASIS OF THE
INFORMATION THAT IS CONTAINED IN THE PROSPECTUS (THE "PROSPECTUS") PUBLISHED
BY THE COMPANY AND THE ISSUER IN CONNECTION WITH THE OFFERING AND ADMISSION
TO TRADING AND LISTING OF THE BONDS TO BE ISSUED BY THE ISSUER AS DESCRIBED
IN THE PROSPECTUS ON THE SIX SWISS EXCHANGE. COPIES OF THE PROSPECTUS ARE
AVAILABLE FREE OF CHARGE AT [UBS AG, PROSPECTUS LIBRARY, P.O. BOX, CH-8098
ZURICH (TELEPHONE NUMBER: +41 (0)44 239 47 03, FACSIMILE: +41 (0)44 239 69
14 OR EMAIL: SWISS-PROSPECTUS@UBS.COM), DURING REGULAR BUSINESS HOURS]

---------------------------------------------------------------------------

Ende der Medienmitteilungen
Originalinhalt anzeigen:
https://eqs-news.com/?origin_id=650dffd7-c0aa-11f0-be29-0694d9af22cf&lang=de

---------------------------------------------------------------------------

Sprache: Deutsch
Unternehmen: DocMorris AG
Walzmühlestrasse 49
8500 Frauenfeld
Schweiz
ISIN: CH0042615283
Börsen: SIX Swiss Exchange
EQS News ID: 2229636

Ende der Mitteilung EQS News-Service
---------------------------------------------------------------------------

2229636 13.11.2025 CET/CEST

°